195 related articles for article (PubMed ID: 8563869)
21. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
[TBL] [Abstract][Full Text] [Related]
22. Pharmaceutic development: mesalazine.
Osterwald HP
Scand J Gastroenterol Suppl; 1990; 172():43-6. PubMed ID: 2353170
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
Healey JN
Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
[TBL] [Abstract][Full Text] [Related]
24. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
25. Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis.
Chuong MC; Christensen JM; Ayres JW
Pharm Dev Technol; 2009; 14(1):116-25. PubMed ID: 18821272
[TBL] [Abstract][Full Text] [Related]
26. Delivery and fate of oral mesalamine microgranules within the human small intestine.
Layer PH; Goebell H; Keller J; Dignass A; Klotz U
Gastroenterology; 1995 May; 108(5):1427-33. PubMed ID: 7729635
[TBL] [Abstract][Full Text] [Related]
27. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
[TBL] [Abstract][Full Text] [Related]
28. Ulcerative colitis therapy: importance of delivery mechanisms.
Rochester J; Abreu MT
Rev Gastroenterol Disord; 2005; 5(4):215-22. PubMed ID: 16369217
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
30. [Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?].
Allgayer H; Klotz U; Böhne P; Schmidt M; Kruis W
Z Gastroenterol; 1994 Nov; 32(11):647-50. PubMed ID: 7886975
[TBL] [Abstract][Full Text] [Related]
31. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
Rijk MC; van Schaik A; van Tongeren JH
Scand J Gastroenterol Suppl; 1988; 148():54-9. PubMed ID: 2906478
[TBL] [Abstract][Full Text] [Related]
32. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
Desreumaux P; Ghosh S
Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():2-9. PubMed ID: 16939423
[TBL] [Abstract][Full Text] [Related]
33. [The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid].
Frol'kis AV
Ter Arkh; 1996; 68(2):75-7. PubMed ID: 8771669
[No Abstract] [Full Text] [Related]
34. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
Nugent SG; Kumar D; Rampton DS; Evans DF
Gut; 2001 Apr; 48(4):571-7. PubMed ID: 11247905
[TBL] [Abstract][Full Text] [Related]
35. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
Rijk MC; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1988 Jan; 23(1):107-12. PubMed ID: 2894070
[TBL] [Abstract][Full Text] [Related]
36. Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
Liu ZC; McClelland RA; Uetrecht JP
Drug Metab Dispos; 1995 Feb; 23(2):246-50. PubMed ID: 7736919
[TBL] [Abstract][Full Text] [Related]
37. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
38. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.
Järnerot G
Drugs; 1989 Jan; 37(1):73-86. PubMed ID: 2651087
[TBL] [Abstract][Full Text] [Related]
39. [Thrombopenia during 5-ASA treatment (mesalazine and olsalazine)].
Benoit R; Grobost O; Bichoffe A; Dol L
Gastroenterol Clin Biol; 1999 Mar; 23(3):410-1. PubMed ID: 10384350
[No Abstract] [Full Text] [Related]
40. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Sandborn WJ; Hanauer SB
Aliment Pharmacol Ther; 2003 Jan; 17(1):29-42. PubMed ID: 12492730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
